Maintenance fees coming due
6 maintenance fees come due in the 12 months from Nov 15, 2026, the next on Jan 4, 2027. Unpaid by Jul 6, 2027, that one lapses early.
A maintenance fee does not end a patent on its due date. It falls due at 3.5, 7.5
and 11.5 years from grant, and the patent lapses only if the fee is still unpaid at the end of the
six month grace period that follows.
| Patent | Title | Holder | Status | Fee due | Lapses if unpaid | Expires | Confidence |
|---|---|---|---|---|---|---|---|
| US 11,690,860 | Treatment of HCV Infected Patients with Cirrhosis In force Fee due Jan 4, 2027 Lapses if unpaid Jul 6, 2027 · Low confidence | Atea Pharmaceuticals, Inc. | In force | Jan 4, 2027 | Jul 6, 2027 | Low confidence | |
| US 11,707,480 | Highly Active Compounds Against COVID-19 In force Fee due Jan 25, 2027 Lapses if unpaid Jul 26, 2027 · High confidence | Atea Pharmaceuticals, Inc. | In force | Jan 25, 2027 | Jul 26, 2027 | High confidence | |
| US 11,738,038 | Highly Active Compounds Against COVID-19 In force Fee due Feb 28, 2027 Lapses if unpaid Aug 30, 2027 · High confidence | Atea Pharmaceuticals, Inc. | In force | Feb 28, 2027 | Aug 30, 2027 | High confidence | |
| US 11,813,278 | Highly Active Compounds Against COVID-19 In force Fee due May 14, 2027 Lapses if unpaid Nov 15, 2027 · High confidence | Atea Pharmaceuticals, Inc. | In force | May 14, 2027 | Nov 15, 2027 | High confidence | |
| US 10,519,186 | Nucleotide Hemi-Sulfate Salt for the Treatment of Hepatitis C Virus In force Fee due Jun 30, 2027 Lapses if unpaid Jan 3, 2028 · High confidence | Atea Pharmaceuticals, Inc. | In force | Jun 30, 2027 | Jan 3, 2028 | High confidence | |
| US 11,975,016 | 2'-Substituted-N6-SUBSTITUTED Purine Nucleotides for RNA Virus Treatment In force Fee due Nov 7, 2027 Lapses if unpaid May 8, 2028 · Low confidence | Atea Pharmaceuticals, Inc. | In force | Nov 7, 2027 | May 8, 2028 | Low confidence |
6 of 6 patents shown. Soonest fee due date first, then patent number.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.